RedHill Biopharma (NASDAQ:RDHL) Stock Crosses Below Two Hundred Day Moving Average of $1.46
RedHill Biopharma (NASDAQ:RDHL) Stock Crosses Below Two Hundred Day Moving Average of $1.46
RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.46 and traded as low as $0.82. RedHill Biopharma shares last traded at $0.87, with a volume of 954,952 shares traded.
在週四的交易中,紅山生物醫藥有限公司(納斯達克代碼:RDHL-GET評級)跌破了200日移動均線。該股的200日移動均線切入位為1.46美元,最低交易價格為0.82美元。紅山生物醫藥的股票最新報0.87美元,總成交量為954,952股。
RedHill Biopharma Price Performance
紅山生物醫藥的價格表現
The company has a debt-to-equity ratio of 9.42, a current ratio of 0.98 and a quick ratio of 0.79. The company has a 50-day simple moving average of $0.94 and a two-hundred day simple moving average of $1.46. The stock has a market capitalization of $45.83 million, a price-to-earnings ratio of -0.46 and a beta of 1.86.
該公司的債務權益比為9.42,流動比率為0.98,速動比率為0.79。該公司的50日簡單移動均線切入位在0.94美元,200日簡單移動均線切入位在1.46美元。該股市值為4,583萬美元,市盈率為-0.46,貝塔係數為1.86。
RedHill Biopharma (NASDAQ:RDHL – Get Rating) last issued its earnings results on Thursday, June 23rd. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.10. RedHill Biopharma had a negative return on equity of 822.29% and a negative net margin of 110.31%. The firm had revenue of $18.24 million for the quarter. During the same period in the prior year, the business earned ($0.53) earnings per share. On average, equities research analysts predict that RedHill Biopharma Ltd. will post -0.95 earnings per share for the current year.
紅山生物醫藥(納斯達克代碼:Rdhl-Get Rating)最近一次發佈收益報告是在6月23日(星期四)。這家生物技術公司公佈了本季度每股收益(0.30美元),比普遍預期的(0.40美元)高出0.10美元。紅山生物醫藥的淨資產回報率為負822.29%,淨利潤率為負110.31%。該公司本季度的收入為1824萬美元。去年同期,該業務實現每股收益(0.53美元)。股票研究分析師平均預測,紅山生物科技有限公司本年度每股收益將為0.95美元。
Institutional Inflows and Outflows
機構資金流入和流出
About RedHill Biopharma
關於雷德希爾生物醫藥公司
(Get Rating)
(獲取評級)
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
紅山生物製藥有限公司是一家專業的生物製藥公司,主要專注於胃腸道和傳染病。該公司推廣胃腸藥物,包括用於治療患有慢性非癌症疼痛的成人阿片類藥物引起的便祕的Movantik;用於治療成人幽門螺桿菌感染的Talicia;以及用於治療成人旅行者腹瀉的Aemcolo。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
- Could Nike Stock be Oversold, but Still Overvalued?
- Is Alcoa A Buy After Strong Q2 Results And More Share Buybacks?
- Will Royal Caribbean's Broadband Partnership Drive Revenue?
- Chip Gear Maker Entegris Has Potential, But Is It Buyable Now?
- DocuSign Has Important Issues to Address When it Reports Earnings
- 免費獲取StockNews.com關於RedHill Biophma(RDHL)的研究報告
- 耐克股票會被超賣,但仍被高估嗎?
- 美國鋁業是在第二季度業績強勁和更多股票回購之後買入的嗎?
- 皇家加勒比的寬帶合作能否推動收入增長?
- 芯片設備製造商Entigis很有潛力,但它現在可以買下嗎?
- DocuSign在報告收益時有重要的問題需要解決
Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《紅山生物報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對RedHill Biophma和相關公司的最新新聞和分析師評級的每日簡要摘要。